Reduction of circulating FII using ASO reduces early mortality in Berkeley sickle mice. (A) Western blot analysis showing levels of circulating FII protein in representative Berkeley sickle mice administered either control ASO (n = 4, lanes 1-4) or FII-specific ASO (n = 4, lanes 6-9) beginning at 3 weeks of age and sacrificed for FII analysis at 15 weeks of age. The plasma FII levels in representative untreated FII^WT (lane 5) and untreated FII^lox/− (lane 10) mice are also shown as additional controls for comparison. (B) PTs of Berkeley sickle mice administered control ASO or FII ASO beginning at 3 weeks of age and sacrificed for plasma analysis at 15 weeks of age. Each symbol represents an individual animal and the bar indicates the median values. Data were analyzed by Mann-Whitney U test; **P < .01. (C) Kaplan-Meier survival analysis of cohorts of Berkeley sickle mice administered either FII ASO (n = 20) or control ASO (n = 20) beginning at 3 weeks of age and continued on weekly ASO treatments until 15 weeks of age. Equal numbers of males and females were enrolled for either control-ASO or FII-specific ASO administration. Among the sickle mice that had early mortalities, the ratio of males to females was 1:1. Comparison of survival curves using log-rank (Mantel-Cox) test; *P < .05.